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Abstract—The potency and nature of the inhibitory effect of various cationic drugs on the transport of choline 
across the placental syncytial microvillus membrane was investigated. Tetraethylammonium, a model substrate 
for organic cation transport, was a poor inhibitor. Enlarging the degree of alkylation of the quaternary ammonium 
increased the inhibitory effect, in proportion with increasing lipophilicity. Log concentration vs % control uptake 
curves showed marked differences in inhibitory potency for the different cationic drugs. Hemicholinium-3 
inhibited mediated choline uptake in the micromolar range, whereas atropine and mepiperphenidol were less 
potent. The H2-receptor antagonists cimetidine, ranitidine, and famotidine inhibited choline uptake in the mil- 
limolar ranges. Dixon analysis revealed a competitive nature of inhibition for hemicholinium-3 and atropine (.K, 
= 40 pM and 1.2 mM, respectively). Cimetidine interacted noncompetitively {Kt = 3,4 mM). Since relatively high 
concentrations were needed to reach half maximal inhibition, impairment of fetal choline supply due to maternal 
drug use during pregnancy is not to be expected.
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Choline, a cationic quaternary ammonium compound, is 
an essential substrate for adequate growth and develop­
ment of the fetus. Choline serves as a substrate for the 
synthesis of phospholipids and acetylcholine. Since the 
human placenta and fetus do not synthesize choline, fetal 
supply is highly dependent on the proper transfer of this 
nutrient from maternal to fetal circulation [1]. The initial 
step in placental transfer involves uptake across the syn­
cytial microvillus membrane of the trophoblast. In the 
perfused human placental cotyledon, trans-placental 
transfer was slow in contrast to the fast and high pla­
cental uptake [2]. Since there was a small excess trans- 
placental choline transfer in comparison with the extra­
cellular marker mannitol, preferentially towards the fetal 
circulation, the human placenta possesses a unidirec­
tional pathway for choline in the maternal to fetal direc­
tion. Placental choline uptake at the maternal side was
inhibited by choline itself and at the fetal side by HC-34 
a well-known competitive inhibitor of choline transport,
suggesting the existence of specific transport systems at 
both sides of the trophoblast. Evidence for mediated tro-
t  Corresponding author: Frans G. M. Russel, Ph.D., Depart­
ment of Pharmacology 233, Faculty of Medical Sciences, Uni­
versity of Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The 
Netherlands. Tel. (31)243613691; FAX (31)243614214.
t  Abbreviations: HC-3, hemicholinium-3; Hepes, 2-amino- 
hydroxyethylpiperazine-N-2-ethanesulfonic acid; Mes, 2(N- 
morpholino)ethanesulfonic acid; NMN, n-methylnicotinamide; 
pH(, pH inside the vesicle; pH0, pH outside the vesicle; SMMV, 
syncytial microvillus membrane vesicles; TMA, tetramethyl- 
ammonium-bromide; TEA, tetraethylamrnoniurn-bromide; 
TPrA, tetrapropylammonium-bromide; TBA, tetrabutylammo- 
nium-hydrogensulfate; TPeA, tetrapentylammonium-bromide; 
THA, tetrahexylammonium-bromide; val, valinomycin.
phoblastic choline uptake was also found in human pla­
cental fragments, which accumulated choline against a 
concentration gradient, inhibitable by HC-3 with a K,- of 
0.45 mM. However, because uptake in fragments is the 
net result of transport across both the syncytial microvil­
lus and basal membranes, it is impossible to differentiate 
between inhibition of the choline transporter at both 
sides of the trophoblast. Isolated vesicles of these mem­
branes are a more appropriate tool for investigating the 
location and nature of such interactions. Recently, we 
described the mechanisms of choline uptake into isolated 
SMMV of human term placenta [3]. Uptake was not 
sodium-dependent or coupled to proton transport. An 
inside negative membrane potential enhanced choline 
uptake, showing that a negatively charged inner mem­
brane surface acts as a driving force for trophoblastic 
choline uptake. Mediated transport was confirmed by the 
ira/w-stimulatory effect of unlabeled choline and cis~ 
inhibitory effects of HC-3, the organic cation transport 
inhibitor mepiperphenidol, and H2~receptor antagonists.
and NMN, did not inhibit choline transport. Further­
more, we found that uptake under /ram-stimulation con­
ditions was saturable with a Km of 550 fiM. Our results 
were confirmed in a study by Grass), who used the same 
approach [4]. In addition he showed, by studying the 
inhibitory potency of a large number of organic cations, 
that at least two sites of interaction with the placental 
choline transporter can be postulated: a negative site that 
binds with the positively charged nitrogen and a site of 
hydrogen bonding that interacts with the primary alco­
hol. Furthermore, the degree of nitrogen group alkyla­
tion appeared to be of importance.
Since trophoblastic uptake is the rate-limiting step in 
fetal choline supply, interaction of maternally adminis-
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tered drugs with the choline transporter at the microvil­
lus membrane could have clinical implications for fetal 
growth and development. This study was designed to 
investigate further the specificity of the choline trans­
porter at the syncytial microvillus membrane of the hu­
man placental trophoblast, by characterizing the inhibi­
tory potency and nature of the interaction of various 
cationic drugs.
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MATERIALS AND METHODS
Chemicals
*
[3H]~Choline was obtained from Amersham (Buck-
controlTM A  TEA TPrA T BA  TPcA THA
inghamshire, U.K.). Cimetidine was kindly donated by Fig. Effect of 1 mM cis concentrations of a series of homol-
Smith, Kline & French (Welwyn Garden City, Herts, 
U.K.), and mepiperphenidol and famotidine by Merck, 
Sharp & Dohme (Rahway, NJ, U.S.A.). All other chem­
icals were purchased from either Sigma (St. Louis, MO, 
U.S.A.), Merck (Darmstadt, Germany), or Boehringer
ogous quaternary ammonium compounds on uptake of 250 jxM 
[3H]-choline at 10 sec. Vesicles, suspended in 100 mM manni- 
tol, 100 mM KC1, and 10 mM Hepes-Tris, pH = 7.4, were 
pre-equilibrated with 5 mM unlabeled choline and 20 (xM val- 
inomycin at 37°C. Five pL vesicle suspension was added to 195 
uL extravesicular medium. Extravesicular media consisted of
Mannheim (Mannheim, Germany), and were of analyt- 100 mM mannitol, 100 mM KC1, 20 jiM valinomycin, 10 mM
ical grade. GF/F filters were obtained from Whatman 
Int. Ltd. (Maidstone, U.K.).
Preparation o f SMMV
SMMV were prepared from fresh human term placen­
tae according to an established method [5], which was 
further improved upon in our laboratory [3, 6]. Briefly, 
tissue was minced in a Waring blender and stirred for 30 
min to loosen the microvilli. After MgCl2 aggregation 
and differential centrifugation, SMMV were harvested 
and suspended in the appropriate intravesicular buffer 
for uptake studies, to a final protein concentration of 
10—15 mg/mL. Vesicles were frozen in liquid nitrogen 
and stored at -80° for four weeks at the maximum. This 
freezing and storage procedure did not influence choline 
uptake. The alkaline phosphatase enrichment of SMMV 
compared to starting mince, measured according to 
Mircheff and Wright [7], was 24-fold (M0 = 70 ± 15 and 
SMMV = 1690 ±310 ^mol/hr/mg, N -  14). Protein was 
assayed with a Coomassie blue kit (Biorad, Munich, 
Germany).
Uptake studies
Hepes-Tris, pH = 7.4, inhibitor at a specified concentration and 
unlabeled choline to achieve an extravesicular concentration of 
250 pM in the final solution. Values are expressed as % of 
representative control (without inhibitor) uptakes (mean ± SD, 
N  = 3). Control uptake was 5115 ± 625 pmol/mg protein. *P <
0.05.
inhibitory constant (K{) for a competitive inhibitor was 
estimated according to the equation of Cheng-Prusoff: Ki 
= IC50 / (1 + S/Km), where S = choline concentration [9]. 
For Km and Vmax of choline, previously determined val­
ues were used, viz. 550 jaM and 10 nmol/mg/10 sec, 
respectively [3]. In case of a noncompetitive inhibitor, 
IC50 is independent of S, and consequently Kt equals 
IC50. Paired Student’s f-test was used to determine sta­
tistical significance (P < 0.05).
RESULTS
Inhibitory potency of tetraalkylammonium compounds
In our previous study it was found that 5 mM TEA did 
not inhibit choline (250 jxM) uptake into SMMV [3], We 
Uptake of [3H]-choline into SMMV was measured in now investigated whether variation in the degree of al-
quadruplicate at 37° using a rapid filtration technique kyiation of TEA influences inhibitory potency. Enlarg­
ing the alkyl chains at the quaternary ammonium re-Whatman
choline uptake
■ HIM
filters (average pore size 0.7 fxm), and the radioactivity suited in a higher percentage of inhibition (Fig. 1). The 
remaining on the filters counted in a Beckman LS 6000 
LL liquid scintillation counter. Corrections were made
for nonspecific filter binding. The exact conditions of the Table 1. Apparent inhibitory constants of cationic drugs on 
transport experiments are given in the legends. Uptake is ‘1“ ,i ’
expressed as pmol or nmol/mg protein or % of control 
uptake (mean ± SD), N  representing the number of ex­
periments with different placentae.
Data analysis
From concentration vs % uptake curves of three con­
centrations of choline below Km (50, 125, and 250 uM),
Compound IC,„ (mM) K, (mM)
Choline
HC-3
Atropine
Mepiperphenidol
Cimetidine
■■'•f ita
the concentration required to reach half maximal inhibi­
tion (IC50) of several cationic drugs was estimated by 
Ieast-squares nonlinear regression analysis, using the 
computer program GraphPad Inplot 4.0 (GraphPad Soft­
ware Inc., San Diego, CA, U.S.A.). The weighted resid­
ual sums of squares of one- and two-site models were 
compared using the F-test. Transformation of the data 
according to Dixon revealed the nature of inhibition. The
Ranitidine
Famotidine
TEA
0.55 ±0.11 
0.069 ± 0.004 
1.45 ±0.30  
0.85 ±0.55 
3.39 ±0.47  
4.04 ±0.62  
3.80 (N= 1) 
>50 {N= 1)
Wlf.C 'ir
MOOT
0.039 ± 0.009* 
1.24 ±0.10*
3.39 ± Q.47t
IC50 values determined from inhibition curves at a choline 
concentration of 250 |i.M and inhibitory constants K, (* com­
petitive; f  noncompetitive) determined from inhibition curves 
at 50, 125, and 250 |iM choline. Values are presented as means 
± SD, N  = 3, except for famotidine and TEA.
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Fig. 2. Inhibition of 250 (J.M [3H]-choline uptake into SMMV at 10 sec under trans-stimulation conditions by various organic 
cations. Experimental conditions were the same as described in the legend of Fig. 1. Values are expressed as % of representative 
control uptakes vs log concentration inhibitor (mM). Each point represents the mean ± SD of three experiments with three
placentae, except for famotidine and TEA (N = 1).
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increase in inhibitory potency of the compounds corre- ¿ 
sponded well with the increase in lipophilicity as given 
by their calculated log P values [10]. Because of the 
surface tension lowering properties of tetraalkylammo- * 
nium compounds, we verified whether the vesicles 
stayed intact in the presence of the inhibitors. Only in the 
presence of THA was the equilibrium uptake of 250 |iM 
choline at 60 min significantly reduced as compared 
with control uptake. The other compounds did not inter­
fere with the membrane integrity.
Inhibition o f choline uptake by several organic cations
Plots of log concentration inhibitor vs % of control 
uptake of 250 (xM choline are shown in Fig. 2. The 
results of the nonlinear regression analysis of the typi­
cally sigmoid shaped curves are summarized in Table 1. 
Marked differences in inhibitory potency can be seen 
between the organic cations tested. HC-3 inhibited 
choline uptake for 50% at a relatively low concentration, 
whereas the organic cation transport inhibitor mepiper- 
phenidol and the anticholinergic drug atropine were less 
potent inhibitors. The H2-receptor antagonists cimeti- 
dine, ranitidine, and famotidine showed IC50 values only 
in the mM ranges. For TEA only a rough estimate of the 
IC50 value could be made, because of the very high 
concentrations (>10 mM) necessary to achieve half max­
imal inhibition. In all cases a two-site model did not fit 
the data better than a one-site model (P > 0 .2).
Nature of interaction with the choline transporter
Although IC50 values provide a good measure of in­
hibitory potency, they cannot explain the nature of the 
interaction. We used the method of Dixon analysis to 
evaluate the type of choline transport inhibition by HC- 
3, atropine, and cimetidine. The concentration-depen­
dent inhibition of these compounds was measured at 
three choline concentrations: 50, 125, and 250 ^M. In­
creasing the substrate concentration decreased the inhib­
itory effectiveness of HC-3 and atropine, resulting in a 
lower IC50 value at a lower choline concentration. Trans­
formation of the data according to Dixon showed that the 
lines intersected above the X  axis and to the left of the Y 
axis, indicating a competitive mode of interaction of 
HC-3 and atropine with the choline transporter (Fig. 3).
K¡ values for competitive inhibition, calculated from the 
Cheng-Prusoff equation for the three choline concentra­
tions, were 40 |xM for HC-3 and 1.2 mM for atropine 
(Table 1). In contrast, the IC50 value for cimetidine was 
independent of the choline concentration. Dixon analysis 
resulted in an intersection of the lines on the X axis, 
consistent with a noncompetitive type of interaction 
(Fig. 3). Consequently, the K, for cimetidine equalled the 
ICjo value of 3.4 mM (Table 1).
DISCUSSION
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Fig. 3. Dixon plots of the interaction of HC-3, atropine, and 
cimetidine with choline. Concentrations of extravesiculor [ ’H]* 
choline were 50, 125, and 250 |iM. Experimental conditions 
were the same as described in the legend of Fig. 1, cxcept that 
in the case of 50 |xM choline, 5 |iL vesicle suspension was
added to 495 uL extravcsicular medium,The present study demonstrates that several cationic 
drugs inhibited human placental choline transport across 
the syncytial microvillus membrane with different inhib­
itory potencies. HC-3 and atropine appeared to be com- creased the inhibitory effect in proportion with increas- 
petitive inhibitors, whereas cimetidine interacted non- ing lipophilicity.
competitively. TEA, a model substrate for organic cation Wright et al. postulated a set of structural elements
transport in various tissues, only inhibited choline trans- important for interaction with the choline transporter: (a) 
port at very high concentrations. Enlarging the degree of a terminal hydroxyl group; (b) the positive charge of the 
alkylation of this quaternary ammonium compound in- nitrogen; and (c) the presence of at least two free methyl
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groups at the positive nitrogen [11]. The placental tions in the Dixon plot (HC-3 -  0.12, atropine ~ 0.07) 
choline transporter appeared to have a similar substrate corresponded well with the l/V n%m value of 0 . 10, pro
specificity [4]. Small quaternary ammonium compounds confirmation
and
carrier
interacted competitively [18]. Although Grass! did not 
report a Kt value for HC-3, a value of 92 jxM can be
whereas TMA showed no affinity for the human placen- calculated from his data [4]. In 
tal and rabbit renal choline transporter [4, 11]. The in- ments a K( of 450 fiM for HC-3 was reported [ I),
quaternary we es in
is
is almost 10-fold higher than the
pounds to interact with the choline transporter was as- isolated human placental SMMV.
sumed to be due to steric hindrance, viz. die masking of most likely due to the different experimental techniques
the positive nitrogen [11, 12], The failure of TEA, for used. An inhibition constant
instance, to interact with the choline transporter was fur- merely a hybrid parameter from interaction
in
confirmed
uptake
transporters at mie and basal side of the tro t a
phoblast, whereas the inhibitory effect in
brush-border membrane vesicles [11-13]. In the present crovillus membranes can only 
study TMA, TEA, and TPrA did not inhibit or poorly tion
inhibited placental choline transport. In spite of a lack of Therefore, estimating inhibitory paramctc 
determinants important for interaction with the choline transport proteins is more m mem
further branes. However, the net effect on the transfer
suited in a significant inhibition of placental choline in maternal to fetal direction should be 
transport by TBA, TPeA, and THA. For TPeA this was more physiologically-based models, such 
also observed in rabbit renal brush-border membranes cell culture or cotyledon perfusion models
We[ 11], and in the study by Grassl [4] a higher degree of 
inhibition of choline uptake was found in the presence of interact with human placental choline transport across 
trimethylphenylammonium, as compared to no signifi- the syncytial microvillus membrane in a competitive and
noncompetitive way. Competitive inhibition was seen in 
the p.M and low mM
cant inhibition with TMA. The reduced choline uptake 
the presence of the more lipophilic quaternary amm 
nium compounds is likely to be of noncompetitive nature inhibition was seen in the high mM ranges, indicating a 
[14]. The higher degree of alkylation probably facilitates nonspecific interaction with the biomembrane. Since rcl
a nonspecific interaction (e.g. solubilization into the atively high concentrations were needed to reach half 
membrane or interaction with an allosteric binding site at maximal inhibition, impairment of fetal choline supply 
the transport protein, thereby interfering with the ability in vivo due to maternal drug use during pregnancy is not
carrier
Cimetidine has affinity for the organic cation-proton
to be expected.
antiporter
currently available. However, in
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membranes an affinity of choline for the organic cation- 
proton antiporter has been demonstrated, since choline 
inhibited TEA transport [11, 16]. Our data provide evi­
dence that H2-receptor antagonists inhibit choline uptake 
noncompetitively. The measured IC50 values were in the 
mM range, and the inhibitory potency of cimetidine was 
not dependent on choline concentration, resulting in an
intersection of lines on the abscissa after Dixon trans- Welsch F, Studies on accumulation and metabolic fate ut
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